PTCT:NGS-PTC Therapeutics Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 47.86

Change

+1.93 (+4.20)%

Market Cap

USD 0.40B

Volume

1.62M

Analyst Target

USD 60.30
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+1.99 (+0.45%)

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

+13.54 (+2.29%)

USD 65.38B
ARGX argenx NV ADR

+4.71 (+0.82%)

USD 34.54B
ALNY Alnylam Pharmaceuticals Inc

+7.34 (+2.57%)

USD 32.75B
ONC BeiGene, Ltd.

+6.27 (+2.61%)

USD 27.70B
SMMT Summit Therapeutics PLC

+0.17 (+0.65%)

USD 27.07B
RPRX Royalty Pharma Plc

+0.01 (+0.03%)

USD 18.40B
INSM Insmed Inc

+2.85 (+4.29%)

USD 11.84B
INCY Incyte Corporation

+1.11 (+1.71%)

USD 11.42B
BMRN Biomarin Pharmaceutical Inc

+0.46 (+0.79%)

USD 11.29B

ETFs Containing PTCT

MSGR 6.14 % 0.00 %

N/A

N/A
IBRN iShares Trust - iShares N.. 4.03 % 0.00 %

+0.37 (+0%)

USD 3.31M
SBIO ALPS Medical Breakthrough.. 3.18 % 0.50 %

+0.91 (+0%)

USD 0.08B
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

+0.14 (+0%)

N/A
BIOT 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.03% 76% C+ 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.03% 76% C+ 75% C
Trailing 12 Months  
Capital Gain 31.23% 85% B 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.23% 85% B 82% B
Trailing 5 Years  
Capital Gain -4.09% 77% C+ 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.09% 77% C+ 38% F
Average Annual (5 Year Horizon)  
Capital Gain 2.14% 56% F 50% F
Dividend Return 2.14% 55% F 45% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 43.30% 69% C- 41% F
Risk Adjusted Return 4.93% 57% F 42% F
Market Capitalization 0.40B 93% A 86% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 6.79 49% 81%
Price/Book Ratio 1,743.27 0% 0%
Price / Cash Flow Ratio -32.55 95% 92%
Price/Free Cash Flow Ratio 2.23 11% 54%
Management Effectiveness  
Return on Equity -7,740.12% 0% 0%
Return on Invested Capital -23.76% 70% 31%
Return on Assets 24.42% 100% 100%
Debt to Equity Ratio -192.10% 92% 95%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.